Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.34
+2.10 (3.49%)
At close: Feb 6, 2026, 4:00 PM EST
61.00
-1.34 (-2.15%)
After-hours: Feb 6, 2026, 7:39 PM EST
Cytokinetics Employees
Cytokinetics had 498 employees as of December 31, 2024. The number of employees increased by 75 or 17.73% compared to the previous year.
Employees
498
Change (1Y)
75
Growth (1Y)
17.73%
Revenue / Employee
$175,122
Profits / Employee
-$1,509,928
Market Cap
7.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | 184 | 28 | 17.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 414 |
| Rhythm Pharmaceuticals | 283 |
| Krystal Biotech | 275 |
| Kymera Therapeutics | 225 |
| Nuvalent | 218 |
CYTK News
- 12 days ago - Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 17 days ago - The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - Business Wire
- 19 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Cytokinetics: Small Label Differences With Big Commercial Stakes - Seeking Alpha
- 6 weeks ago - Cytokinetics Wins FDA Nod For Heart Drug Myqorzo - Benzinga
- 6 weeks ago - Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript - Seeking Alpha